600216.SHG Zhejiang Medicine Co Ltd
- Market cap
- CNY 10.8B
- P/E
- 17.1x
- P/B
- 0.92x
- ROE
- 8.0%
- Dividend yield
- 3.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600216.SHG undervalued?
Graham number600216.SHG trades 16.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Medicine Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Medicine Co Ltd yet.
Zhejiang Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofl…
Full company profileZhejiang Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.28B | 5.69B | 6.86B | 7.04B | 7.33B | 9.13B | 8.12B | 7.79B | 9.38B | 8.88B | 8.33B |
| Gross Profit | 1.40B | 1.60B | 2.77B | 2.77B | 2.92B | 3.60B | 2.68B | 2.40B | 3.78B | 3.08B | 2.94B |
| Operating Income | 549M | 333M | 469M | 409M | 883M | 1.18B | 505M | 380M | 1.22B | 1.08B | 1.05B |
| EBITDA | 929M | 649M | 915M | 756M | 1.28B | 1.75B | 1.17B | 706M | 1.90B | 1.77B | 910M |
| Net Income | 450M | 253M | 365M | 343M | 717M | 1.05B | 540M | 430M | 1.16B | 873M | 924M |
| EPS | 0.48 | 0.27 | 0.38 | 0.36 | 0.75 | 1.09 | 0.56 | 0.45 | 1.21 | 0.91 | 0.96 |
| Balance Sheet | |||||||||||
| Total Assets | 8.81B | 9.79B | 10.0B | 10.4B | 10.5B | 12.5B | 12.4B | 12.8B | 13.8B | 14.1B | 14.7B |
| Total Liabilities | 1.82B | 2.01B | 1.96B | 2.11B | 2.47B | 3.35B | 2.72B | 2.79B | 2.93B | 3.00B | 2.86B |
| Shareholders' Equity | 6.98B | 7.29B | 7.65B | 7.86B | 7.67B | 8.78B | 9.26B | 9.63B | 10.6B | 10.9B | 11.5B |
| Cash & Short-term Investments | 1.32B | 1.42B | 1.50B | 1.61B | 1.90B | 2.22B | 1.89B | 1.79B | 2.26B | 3.17B | 3.17B |
| Total Debt | 439M | 409M | 495M | 650M | 951M | 878M | 802M | 431M | 442M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 336M | 503M | 580M | 447M | 1.26B | 1.14B | 521M | 634M | 1.22B | 1.89B | - |
| Capital Expenditure | 382M | 570M | 439M | 574M | 535M | 940M | 976M | 797M | 689M | 446M | 498M |
| Free Cash Flow | -45.6M | -66.5M | 141M | -126M | 721M | 197M | -455M | -163M | 534M | 1.44B | 294M |
| Ratios | |||||||||||
| ROE | 6.5% | 3.5% | 4.8% | 4.4% | 9.3% | 11.9% | 5.8% | 4.5% | 10.9% | 8.0% | 8.0% |
| ROA | 5.1% | 2.6% | 3.6% | 3.3% | 6.8% | 8.3% | 4.3% | 3.4% | 8.4% | 6.2% | 6.3% |
| Net Profit Margin | 8.5% | 4.4% | 5.3% | 4.9% | 9.8% | 11.5% | 6.6% | 5.5% | 12.4% | 9.8% | 11.1% |
| Debt to Equity | 0.06x | 0.06x | 0.06x | 0.08x | 0.12x | 0.10x | 0.09x | 0.04x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Medicine Co Ltd dividends
- Dividend yield
- 3.47%
- Forward dividend
- 0.28 CNY
- Payout ratio
- 43.1%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 377M | 0.39 | 43.1% |
| 2024 | CNY 143M | 0.15 | 12.3% |
| 2023 | CNY 192M | 0.20 | 44.7% |
| 2022 | CNY 318M | 0.33 | 59.0% |
| 2021 | CNY 220M | 0.23 | 21.1% |
| 2020 | CNY 1.01B | 1.05 | 140.3% |
| 2019 | CNY 144M | 0.15 | 41.9% |
| 2018 | CNY 98.1M | 0.10 | 26.9% |
| 2017 | CNY 160M | 0.17 | 63.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 18:10 on Oct 9, 2013.
Who owns Zhejiang Medicine Co Ltd
- Insiders 42.10%
- Institutions 3.94%
- Public & others 53.96%
- Shares outstanding 962M
- Free float 583M
Zhejiang Medicine Co Ltd company profile
- Company name
- Zhejiang Medicine Co Ltd
- Ticker
- 600216.SHG
- ISIN
- CNE0000010J2
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 11, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,417
- Fiscal year end
- December
- Address
- No. 168, Zhiyuan Middle Avenue, Shaoxing, China, 312366
- Phone
- 86 575 8521 1979
- Website
- zmc.top
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, vancomycin hydrochloride injection, and injectable teicoplanin products. The company was incorporated in 1997 and is headquartered in Shaoxing, China.
Zhejiang Medicine Co Ltd management
8- Mr. Hongwei WangPresident & Director · born 1969
- Ms. Qirong LiCFO & Financial Director · born 1988
- Mr. Minzhi ShaoBoard Secretary · born 1989
- Mr. Jianhong PingVice President · born 1977
- Mr. Yongbin AnSenior Manager · born 1968
- Ms. Liping LiangVice President · born 1974
- Mr. Xiaoping WangVice President · born 1970
- Guangshan GuoAccounting Supervisor